Since the emergence of the COVID-19 pandemic, various cutaneous manifestations have been reported among infected individuals. Understanding these dermatological symptoms is crucial for early recognition, diagnosis, and appropriate management. This retrospective study investigated the prevalence and types of cutaneous manifestations observed among COVID-19 patients admitted to a designated COVID hospital in Bihar, India. Medical records of COVID-19 patients admitted to the COVID hospital between August 2022 and July were retrospectively reviewed. Patients with documented cutaneous manifestations during their hospitalization were included in the study. Data on patient demographics, clinical characteristics, and dermatological findings were collected and analysed. This study included 500 patients with moderate-to-severe COVID-19, where more than half were aged >60 years, and 48% exhibited severe cutaneous manifestations, with erythematous rash (38%) being the most common symptom, while vesicular lesions were associated with severe COVID-19, and erythematous rash and urticaria with mild-to-moderate disease, and post-COVID-19 skin complications were reported in 15% of recovered patients, with post-inflammatory hyperpigmentation (7%) and pruritus (5%) being the most common. This retrospective study sheds light on the occurrence of cutaneous manifestations in COVID-19 patients admitted to a COVID hospital in Bihar, India. Early recognition of these dermatological signs is crucial for timely diagnosis and appropriate management. Further research is warranted to investigate the underlying mechanisms and potential implications of these cutaneous symptoms in the context of COVID-19.

Since the emergence of the COVID-19 pandemic, various cutaneous manifestations have been reported among infected individuals. Understanding these dermatological symptoms is crucial for early recognition, diagnosis, and appropriate management. This retrospective study investigated the prevalence and types of cutaneous manifestations observed among COVID-19 patients admitted to a designated COVID hospital in Bihar, India. Medical records of COVID-19 patients admitted to the COVID hospital between August 2022 and July were retrospectively reviewed. Patients with documented cutaneous manifestations during their hospitalization were included in the study. Data on patient demographics, clinical characteristics, and dermatological findings were collected and analysed. This study included 500 patients with moderate-to-severe COVID-19, where more than half were aged >60 years, and 48% exhibited severe cutaneous manifestations, with erythematous rash (38%) being the most common symptom, while vesicular lesions were associated with severe COVID-19, and erythematous rash and urticaria with mild-to-moderate disease, and post-COVID-19 skin complications were reported in 15% of recovered patients, with post-inflammatory hyperpigmentation (7%) and pruritus (5%) being the most common. This retrospective study sheds light on the occurrence of cutaneous manifestations in COVID-19 patients admitted to a COVID hospital in Bihar, India. Early recognition of these dermatological signs is crucial for timely diagnosis and appropriate management. Further research is warranted to investigate the underlying mechanisms and potential implications of these cutaneous symptoms in the context of COVID-19.